Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Metabolic Effects of Rosiglitazone and Metformin in Greek Patients with Recently Diagnosed Type 2 Diabetes

FOTIOS ILIADIS, NIKOLAOS P. KADOGLOU, APOSTOLOS HATZITOLIOS, MICHALIS KARAMOUZIS, MILTIADIS ALEVIZOS and DIMITRIOS KARAMITSOS
In Vivo November 2007, 21 (6) 1107-1114;
FOTIOS ILIADIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NIKOLAOS P. KADOGLOU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
APOSTOLOS HATZITOLIOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: axatzito@med.auth.gr
MICHALIS KARAMOUZIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MILTIADIS ALEVIZOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DIMITRIOS KARAMITSOS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The aim of this study was to evaluate the comparative effects of rosiglitazone and metformin on metabolic parameters in recently diagnosed type 2 Greek diabetic patients. A total of 41 drug-naive individuals, with recently diagnosed type 2 diabetes, were randomized in 3 groups: DIET, diet alone; ROSI, diet plus rosiglitazone; and MET, diet plus metformin. Anthropometric indexes, blood pressure, hematological and biochemical parameters were estimated at baseline and after 18 weeks of treatment. We observed a significant decrease of fasting glucose (FBG) (p<0.001), glycated haemoglobin (HbA1c) (ROSI: p=0.001, MET: p<0.001), homeostasis model assessment for insulin resistance (HOMA-IR) (ROSI: p=0.006, MET: p=0.009) and glutamic pyruvic transaminase (SGPT) (ROSI: p=0.004, MET: p=0.003) in both ROSI and MET groups. Metformin significantly reduced fasting insulin (p=0.04), body weight (p=0.026), body mass index (BMI) (p=0.022), waist circumference (p=0.022) and gamma glutamyl transpeptidase (Á-GT) (p=0.039), while rosiglitazone decreased blood pressure (systolic: p=0.05, mean: p=0.03) and alkaline phosphatase (ALP) (p=0.001) compared to baseline values. Combined intervention with rosiglitazone and diet led to a slight, not significant, weight loss. Rosiglitazone and metformin are equaly effective in controling diabetes, decreasing insulin resistance and improving liver function. However, considering the more favorable effects of metformin on body composition and its documented cost-effectiveness, it seems to be preferable in newly diagnosed Greek diabetic patients.

  • Metformin
  • rosiglitazone
  • diabetes type 2

Footnotes

  • Received August 2, 2007.
  • Revision received September 28, 2007.
  • Accepted October 2, 2007.
  • Copyright © 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

In Vivo
Vol. 21, Issue 6
November-December 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic Effects of Rosiglitazone and Metformin in Greek Patients with Recently Diagnosed Type 2 Diabetes
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Metabolic Effects of Rosiglitazone and Metformin in Greek Patients with Recently Diagnosed Type 2 Diabetes
FOTIOS ILIADIS, NIKOLAOS P. KADOGLOU, APOSTOLOS HATZITOLIOS, MICHALIS KARAMOUZIS, MILTIADIS ALEVIZOS, DIMITRIOS KARAMITSOS
In Vivo Nov 2007, 21 (6) 1107-1114;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Metabolic Effects of Rosiglitazone and Metformin in Greek Patients with Recently Diagnosed Type 2 Diabetes
FOTIOS ILIADIS, NIKOLAOS P. KADOGLOU, APOSTOLOS HATZITOLIOS, MICHALIS KARAMOUZIS, MILTIADIS ALEVIZOS, DIMITRIOS KARAMITSOS
In Vivo Nov 2007, 21 (6) 1107-1114;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Surgical Treatment and Prognosis of Soft Tissue Sarcoma in Patients Aged 85 Years and Older
  • Neutrophil-to-Lymphocyte Ratio as a Biomarker for Postoperative Complications in Crohn’s Disease
  • IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn’s Disease: Study of IgA1 and IgA2 Expression in Glomeruli
Show more Clinical Studies

Similar Articles

In Vivo

© 2025 In Vivo

Powered by HighWire